This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignees: The University of British Columbia, Cdrd Ventures Inc., Sangamo Therapeutics France. Active years: 2023-2024.
Company Filing History:
2 out of 958 
1 out of 3 
1 out of 2 Years Active: 2023-2024
Title: Megan Levings: Innovator in Chimeric Antigen Receptor Technology
Introduction
Megan Levings is a remarkable inventor based in Vancouver, Canada. She has made significant contributions to the field of immunology, particularly through her development of innovative antibodies and chimeric antigen receptor (CAR) methods. With a total of two patents, Levings continues to advance medical science and therapeutic interventions.
Latest Patents
Megan Levings holds two notable patents. The first, titled "Anti-HLA-A2 antibodies and methods of using the same," introduces humanized anti-HLA-A2 antibodies that can be utilized within chimeric antigen receptors. These CARs are designed to be expressed in human cells, allowing for targeted binding to HLA-A2. The invention further encompasses modified cells that incorporate the antibodies and CARs along with outlined methods of utilizing these modified cells in therapeutic applications.
The second patent, "Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof," details a novel anti-HLA-A2 antibody and a chimeric antigen receptor that includes this specific antibody. This invention also explores immune cells that express the chimeric receptor and discusses its therapeutic uses, particularly in the treatment or prevention of graft rejection and graft-versus-host disease (GVHD).
Career Highlights
Throughout her career, Megan Levings has worked at prestigious research institutions, including the University of British Columbia and Sangamo Therapeutics in France. Her work is recognized for its impact on immunotherapy and the advancement of cancer treatments, contributing to the growing body of knowledge in the field.
Collaborations
Megan has collaborated with esteemed colleagues, including Caroline Lamarche and Li Zhou. These partnerships have allowed her to share insights and enhance her research, paving the way for significant advancements in immunological therapies.
Conclusion
Megan Levings stands out as a pioneering inventor whose work on anti-HLA-A2 antibodies and chimeric antigen receptors is shaping the future of medical therapies. Her contributions are not only indicative of her innovative spirit but also highlight the importance of collaboration in scientific research. As she continues her work, the field of immunology will undoubtedly benefit from her ongoing discoveries and inventions.